The Alere flu test detected fewer cases of influenza A in a recent study, which researchers attributed to low viral loads.
Although the financial filing sheds increased light on Alere's business, the company is asking for an extension to file its second quarter financial statements.
The PCR-based assays run on the company's Aries system, which itself received FDA clearance in October 2015.
A month after Brexit fears pushed the GenomeWeb Index down half a percent, companies rallied on news of an acquisition and better than expected Q2 performances.
The point-of-care test detects and distinguishes influenza A and B as well as respiratory syncytial virus in about 20 minutes.
The company will soon submit its ePlex instrument and respiratory pathogen panel for US Food and Drug Administration clearance.
Speakers at the CVS meeting in Florida last week spoke about the utility and effectiveness of sequencing approaches in the study of viruses.
The firm recently made strategic hires with commercialization experience in anticipation of bringing its handheld point-of-care device to market.
The company said sales of its XT-8 molecular diagnostics system were strong, despite a lighter-than-expected flu season.
The state department has implemented WGS protocols for influenza A and B to track drug resistance and to better understand how the virus changes from year to year.
A federal judge has ruled that drug companies, device manufacturers, and universities need to provide missing clinical data from hundreds of trials to a federal website, ScienceInsider reports.
A genetic analysis suggests red pandas might actually belong to two different species, New Scientist reports.
NPR reports that the US Centers for Disease Control and Prevention has fixed the problem with some of its SARS-CoV-2 testing kits.
In Nature this week: epigenetic factors that prevent healthy aging and more.